GH
Guardant Health, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers):
breedte van houders +4.8% ·
aandelenstroom -4.7% ·
netto nieuwe posities 0.0%
· formule
Fragmentatie van eigendom: meer houders, kleiner totaalbelang
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.42K | $7.92M | n/a | −1 |
| Q2 2026 | 137 | +11 | 93.62M | $13.95B | +17 | −7 |
| Q1 2026 | 130 | -8 | 97.95M | $8.77B | +5 | −14 |
| Q4 2025 | 137 | +1 | 99.79M | $9.86B | +2 | n/a |
| Q3 2025 | 22 | +1 | 50.89M | $3.18B | +2 | −2 |
| Q2 2025 | 19 | -1 | 51.15M | $2.66B | n/a | −1 |
| Q1 2025 | 17 | -1 | 25.07M | $1.07B | n/a | −1 |
| Q4 2024 | 18 | +2 | 25.10M | $766.76M | +2 | n/a |
| Q3 2024 | 15 | +1 | 25.31M | $580.70M | +2 | −1 |
| Q2 2024 | 14 | n/a | 24.13M | $697.01M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 11.91M | -2.1% | $744.06M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passief) | 11.43M | +4.1% | $714.10M | 0.0% | ▲ Add | 2 | SEC ↗ ×21 |
| 3 | Baillie Gifford ✦ | 5.13M | +6.6% | $320.38M | 0.2% | ▲ Add | 6 | SEC ↗ ×4 |
| 4 | T. Rowe Price ✦ | 4.22M | +139.1% | $263.77M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 3.25M | +69.0% | $203.00M | 0.0% | ▲ Add | 6 | SEC ↗ ×9 |
| 6 | Geode Capital Management ✦ (passief) | 2.94M | +0.6% | $183.51M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passief) | 2.79M | -1.8% | $174.18M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 1.80M | -2.8% | $112.67M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 1.51M | n/a | $94.11M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 10 | JPMorgan Chase ✦ | 987.64K | n/a | $61.71M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 11 | Morgan Stanley ✦ | 982.54K | n/a | $61.39M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 12 | Millennium Management ✦ | 878.58K | -67.7% | $54.89M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 824.26K | -16.5% | $51.50M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 14 | ARK Investment Management ✦ | 795.23K | -71.8% | $49.69M | 0.3% | ▼ Trim | 6 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 531.85K | -21.2% | $33.23M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 304.52K | -89.6% | $19.03M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | Marshall Wace ✦ | 241.31K | Nieuw | $15.08M | 0.0% | New | 1 | SEC ↗ ×2 |
| 18 | Adage Capital Partners ✦ | 152.12K | -50.5% | $9.50M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Point72 Asset Management ✦ | 102.42K | +81.9% | $6.40M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 81.58K | +1.8% | $5.10M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 21 | D. E. Shaw & Co. ✦ | 33.35K | Nieuw | $2.08M | 0.0% | New | 1 | SEC ↗ |
| 22 | Bridgewater Associates ✦ | 4.01K | +3.6% | $250,545 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Marshall Wace | $15.08M | 0.0% |
| D. E. Shaw & Co. | $2.08M | 0.0% |
Verlaten
| Norges Bank | $64.14M | was 0.0% |
| PRIMECAP Management | $3.43M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 481 houders, 137.05M aandelen, $11.53B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 116 aand · $19,242
Director · 69 aand · $11,032
Director · 1.10K aand · $192,432
Director · 826 aand · $144,550
Director · 3.30K aand · $578,888
Director · 1.30K aand · $229,236
Director · 971 aand · $172,330
Director · 116 aand · $20,300
Officer · 7.74K aand · $1.38M
Officer · 4.00K aand · $632,193
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie